UCB reports new Neupro trial data at AAN 2012

UCB is presenting new clinical trial data for its drug Neupro at the 2012 annual meeting of the American Academy of Neurology (AAN) this week.

New studies of the rotigotine transdermal system-based treatment are being presented to demonstrate its impact on the core symptoms of restless legs syndrome (RLS) and on the motor and underlying symptoms of Parkinson's disease.

This comes after the drug was approved by the US Food and Drug Administration earlier this month as a therapy for the signs and symptoms of advanced stage idiopathic Parkinson's disease, as well as for moderate-to-severe primary RLS.

Dr James Zackheim, senior medical director for UCB's central nervous system business unit, said: "The data underscores UCB's continuing commitment to discovering and developing therapies that address unmet medical needs for potentially debilitating central nervous system disorders."

Earlier this month, the company reported positive data from a study of Cimzia, showing its efficacy against ankylosing spondylitis.